BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology

Secondary purposes are :

• To confirm the presence of plasma soluble form of PD-L1 in others malignancies
• To study surface expression of PD-L1 on circulating tumour cells with multiparameter fow cytometry and Veridex® technology in DLBCL and metastatic breast cancer patients
• To study surface expression of PD-L1 on circulating endothelial cells in DLBCL, Hodgkin lymphoma and metastatic breast cancer patients (subpart ended in late 2012)
• To study surface expression of PD-L1 on different types of leukocytes (monocytes, B and T lymphocytes)
• To separate circulating tumour cells expressing PD-L1 by immunomagnetic or Cell-sorting method
• To develop ELISPOT technique to study the release of soluble PD-L1 in culture supernatants of selected cells (subpart ended mid 2013)
• to evaluate the correlation between the expression of PD-L1 in the plasma and *) the expression of PD-L1 in the tumor, **) the expression of PD-L1 and other molecules in the bronchoalveolar liquid (whenever available from routine) in non-small cell lung cancer
• to evaluate the response to treatment according to plasma PD-L1 expression in non-small cell lung cancer
• to evaluate the susceptibility to develop a disease according to the single nucleotide polymorphisms of the PD-L1 gene in DLBCL and non-small cell lung cancer
• Constitution of the different cohorts and collection of samples Main cohort : de novo DLBCL at diagnosis Secondary cohorts: Hodgkin's lymphoma, metastatic breast cancer, non small cell lung cancer Control cohorts : healthy volunteers (blood donors), patients with immune thrombocytopenia (ITP)
• Quantification of plasma soluble PD-L1 in the different cohorts

Inclusion criteria

General inclusion criteria :

• Age ≥ 18 years and ≤ 75 years,
• Life expectancy more than 4 months
• Signed informed consent obtained
• Social security affiliation is mandatory
• Non previously treated (even by corticotherapy),
• HIV negative, HBs negative, HCV negative

Inclusion criteria

for DLBCL patients :

• A biopsy proven diagnosis of de novo DLBCL according to the current WHO criteria,
• Immunohistochemistry for GCB/nonGC classification according to Hans' algorithm
• Patients with advanced-stage disease defined as Ann Arbor stages III or IV, or stages I or II with bulky disease (>7cm)

Inclusion criteria

for non-small cell lung cancer patients :

• A biopsy proven diagnosis of de novo non-small cell lung cancer (all stages) according to the current WHO criteria

Inclusion criteria

for Hodgkin's lymphoma patients :

• A biopsy proven diagnosis of Hodgkin's lymphoma according to the current WHO criteria

Inclusion criteria

for metastatic breast cancer or with lymph node involvement :

• A biopsy proven diagnosis infiltrating lobular or ductal breast carcinoma
• with lymph node involvement or metastasis

Inclusion criteria

for patients with immune thrombocytopenia (ITP) :

• Primary ITP was defined by the IWG as a platelet count less than 100 G/L in the absence of other causes or disorders that may be associated with thrombocytopenia.
• Bone marrow examination excluding a central aetiology of thrombocytopenia

Inclusion criteria

for healthy volunteers :

• Inclusion criteria for blood donation according to the Etablissement Français du Sang (EFS) criteria

Exclusion criteria

General non-inclusion criteria :

• Age < 18 years et > 75 years,
• Pregnant women,
• Person legally involved in a case
• No social security affiliation
• Signed informed consent not obtained,
• Preliminary treatment (even corticoid treatment).
• HIV positive, HBs positive, HCV positive

Non-inclusion criteria for DLBCL patients :

• Lymphoma other than DLBCL,
• Transformation of a low grade lymphoma to a high grade lymphoma (DLBCL),
• Extranodal marginal zone lymphoma of MALT lymphoma,
• Post-transplant lymphoproliferative disorders,
• Lymphoblastic lymphoma,
• Burkitt's lymphoma,
• Carcinoma or history of carcinoma except in situ cervical carcinoma.

Non-inclusion criteria for non-small cell lung cancer patients : None

Non-inclusion criteria for Hodgkin patients :

• Non Hodgkin's lymphoma

Non-inclusion criteria for metastatic breast cancer or with lymph node involvement :

• Carcinoma other than infiltrating lobular or ductal breast carcinoma
• Chemotherapy in 30 days preceding the inclusion
• Hormonotherapy in 7 days preceding the inclusion
• Carcinoma or history of carcinoma except in situ cervical carcinoma.
• Hemoglobin level < 10g/dl

Non-inclusion criteria for patients with immune thrombocytopenia (ITP) :

• Central aetiology of the thrombocytopenia

Non-inclusion criteria for healthy volunteers :

• Exclusion criteria for blood donation according to the Etablissement Français du Sang (EFS) criteria